Comparative in vitro activity of quinupristin/dalfopristin against multidrug resistant Enterococcus faecium

Diagn Microbiol Infect Dis. 1996 Jul;25(3):127-31. doi: 10.1016/s0732-8893(96)00123-x.

Abstract

The in vitro susceptibilities of 82 strains of vancomycin resistant Enterococcus faecium (VREF), (49 vanA and 33 vanB) from over 13 hospitals in Europe and United States were studied. The MIC for several antibiotics showed high levels of resistance to vancomycin, ampicillin, gentamicin, and imipenem. All VREF strains were highly susceptible to quinupristin/dalfopristin with a MIC 90% of 0.5 microgram/ml for both vanA and vanB phenotypes. Time-kill and synergy studies of VREF for quinupristin/dalfopristin alone and quinupristin/dalfopristin in combination with several antibiotics (ampicillin, gentamicin, ciprofloxacin, rifampin and novobiocin) did not show bactericidal activity. In induction experiments using SF6550, (VREF, a vanA strain), quinupristin/dalforpristin showed a delay in the expression of vancomycin resistance by 2.5 hours. The results of this study show quinupristin/dalfopristin to have excellent in vitro activity versus multiple resistant E. faecium.

Publication types

  • Comparative Study

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Drug Resistance, Multiple*
  • Enterococcus faecium / drug effects*
  • Enterococcus faecium / isolation & purification
  • Humans
  • Microbial Sensitivity Tests
  • Virginiamycin / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Virginiamycin
  • quinupristin-dalfopristin